Seroatlas · Human Serome Atlas

IFNL2

Interferon lambda-2

Also known as: IFNL2_HUMAN, IL-28A, IL28A

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8IZJ0
Gene: IFNL2
Ensembl: ENSG00000183709
Chromosome: 19
Canonical length: 200 aa
Protein class: Predicted secreted proteins
Secretome location: Secreted to blood

OverviewNCBI Gene

This gene encodes a cytokine distantly related to type I interferons and the IL-10 family. This gene, interleukin 28B (IL28B), and interleukin 29 (IL29) are three closely related cytokine genes that form a cytokine gene cluster on a chromosomal region mapped to 19q13. Expression of the cytokines encoded by the three genes can be induced by viral infection. All three cytokines have been shown to interact with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor, beta (IL10RB) and interleukin 28 receptor, alpha (IL28RA). [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

200 residues, UniProt reviewed canonical sequence.

>Q8IZJ0|IFNL2
     1  MKLDMTGDCT PVLVLMAAVL TVTGAVPVAR LHGALPDARG CHIAQFKSLS PQELQAFKRA
    61  KDALEESLLL KDCRCHSRLF PRTWDLRQLQ VRERPMALEA ELALTLKVLE ATADTDPALV
   121  DVLDQPLHTL HHILSQFRAC IQPQPTAGPR TRGRLHHWLY RLQEAPKKES PGCLEASVTF
   181  NLFRLLTRDL NCVASGDLCV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against IFNL2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.38
Highest tissue expression: 0.4 nTPM

Expression across tissuesHPA

Tissue

pancreas: 0.4 nTPM
testis: 0.2 nTPM
skin: 0.1 nTPM
adipose tissue: 0 nTPM
adrenal gland: 0 nTPM
amygdala: 0 nTPM

Single-cell type

epicardial cells: 2.3 nCPM
granulosa cells: 0.8 nCPM
cdc: 0.1 nCPM
early primary spermatocytes: 0.1 nCPM
epididymal principal cells: 0.1 nCPM
pancreatic acinar cells: 0.1 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

amygdala: 0.3 nTPM
cerebellum: 0.3 nTPM
cerebral cortex: 0.3 nTPM
hippocampal formation: 0.3 nTPM
basal ganglia: 0.2 nTPM
hypothalamus: 0.1 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.87
gnomAD pLI: 0
gnomAD missense Z: -0.24
DepMap mean gene effect: 0.09
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads IFNL2 as an antibody target. Whether an autoantibody or antibody against IFNL2 could matter depends on whether native IFNL2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

IFNL2 is annotated as secreted, so native IFNL2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label IFNL2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...